Heart failure (HF) common, currently affecting 26 million patients worldwide. 1 The majority of the HF population is elderly and/or frail patients that commonly have one or more associated comorbidities. 2 This growing burden of heart failure affecting a particularly at-risk group led the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) to bring together experts to discuss these topical and clinically difficult areas. Now, we are proud to publish individual papers on ageing, demographics, and heart failure, drug treatment of the older patient, the impact of frailty in HF, and how to avoid 'frailtyism'. This is also discussion of the common problems affecting skeletal muscle, both sarcopaenia and cachexia, as well as dementia and cognitive decline and the crucial issue of planning health care for the older patient with HF most effectively by the use of care plans.
In the first paper, Andrew Coats reviews the epidemiology of HF and the impact of the ageing population on this disorder. He reviews the differing pathophysiological mechanisms of heart failure in older patients and their different background disease burden and possibly different and more prevalent burden of comorbidities. 3, 4 He argues strongly for more studies specifically recruiting older HF patients with more comorbidities, to guide realworld practice, and to assess patient-reported outcomes and quality of life rather more than we have in the past. Both the prevalence of comorbidities and mortality increase with age and of course heart failure with reduced ejection fraction (HFrEF) is more common in younger cohorts (and in most randomized clinical trials) compared to the elderly where the less well trialled heart failure with preserved ejection fraction (HFpEF) predominates. The ageing population has changed HF as often an isolated disorder to one where non-cardiovascular comorbidities are common and can affect the modes and causes of death, in a way which makes clinical trial design and monitoring more difficult. Although subgroup analyses of the major HF RCTs have not suggested differing outcomes with age, still very few studies have specifically recruited older HF patients. There is a discussion of the particular effects of comorbidities in this regard.
Ewa A. Jankowska et al. review drug therapy in elderly heart failure patients. They review the evidence-base of pharmacotherapy in elderly patients with heart failure, including the most recent major trials PARADIGM-HF trial, of sacubitril-valsartan combination compared to enalapril in HFrEF and the DAPA-HF trial of dapagliflozin. They summarize that the pharmacotherapy of HFrEF in elderly patients is recommended to be the same as for patients in all other age groups being based on angiotensin converting enzyme (ACE) inhibitors [or angiotensin receptor blocker (ARB) or angiotensin receptor neprilysin inhibitor (ARNI)], betablockers, mineralocorticoid receptors, ivabradine to improve clinical outcomes, along with loop diuretics and sometimes digoxin to further alleviate HF symptoms. 5 They stress the risk of inappropriate prescribing and the risk of side effects because of frailty and the impact of multiple comorbidities. Cristina and Loreena Hill review the issues of frailty in HF and whilst stressing the importance of screening for and detecting frailty within any cohort of HF patients they also caution against 'frailtyism'. Frailtyism they liken to ageism as prejudice or discrimination based on the presence of frailty. They quite rightly point out that because of its major prognostic and therapeutic implications, 6 the identification of frailty is of major importance, 7 and that it is of significance in HF 8 as in any other area of medicine, perhaps even more so than most. They talk about the efforts of the HFA to devise and then validate an objective and easy to use measurement that can help detect and document frailty within a HF population in our effort to prevent or manage poor outcomes in this at-risk group, ultimately enabling more effective and tailored plans of care to suit the needs of the patient. The very limited number of interventional trials to date needs to increased. 9 Later in the issue, Loreena Hill also gives practical advice concerning the need and mechanisms of creating a care plan for the elderly HF patient. 10 We then have review articles written by experts in the field on two complex and partially inter-related complications of HF, that being cachexia and sarcopaenia. 11 Cachexia is a state of energy deprivation or wasting where body weight loss leads to loss of skeletal muscle as well as other tissue compartments. 12 Sarcopaenia, in contrast, is a purer form of skeletal muscle loss and associated functional weakness. Both are common in the elderly, 13, 14 and both are common in HF. 15 Sarcopaenia formally defined as reduced skeletal muscle mass associated with either a decline in muscle strength or low physical performance is common 16 as the populations of developing nations are ageing. 17, 18 It has a particularly high prevalence (>20%) in HF, where it further impairs patients already with markedly reduced exercise capacity due to their HF and leads to an increased hospitalization burden. 19 Sarcopaenia also increases mortality, and impairs quality of life, frequently making the difference between the ability to self-care or not. The pathophysiological mechanisms underlying sarcopaenia are discussed, as is the treatments we have to date to prevent this disabling condition, mainly involving resistance training combined with nutritional protein supplements. Cardiac cachexia (the cachexia complicating HF) has a long history with a first plausible description being found in the writings of Hippocrates. As Dr Lena and colleagues from the leading cachexia centre (Charité, Berlin) review, cachexia is a complex multifaceted disorder characterized by a pathological shift in the balance between anabolism (growth) and catabolism (wasting). It is a common complication of many chronic disease processes, and these include HF. In patients at risk, cachexia is seen crosssectionally in about 10% of HF patients, but longitudinally it is far more incident than that because once acquired it is associated with an extremely high mortality rate, so that sufferers frequently die within months of reaching the cachectic state. There is an urgent need to find new effective therapies 20 and despite extensive effort, the only effective therapy to date remains cardiac transplantation in patients so affected, although beta-blockers have shown some efficacy. 21 The other important organ that suffers 'wasting' as a consequence or in association with HF is the brain, and the resulting dementia and cognitive impairment is a major public health problem as well as a potentially catastrophic complication. Professor Doehner, who may well be unique as a professor in both HF and stroke medicine, reviews the interaction between heart and brain disorders 22 and how in HF patients, especially the older patients strokes, dementia, and depression are all prevalent and the cause of major clinical and management difficulties. Loss of ability to selfcare is a contributor to very poor quality of life and often leads to a dramatic increase in health care expenditure. I recommend this series of up to date review articles to our readership, in our efforts as the HFA to improve the care and quality of life of all HF sufferers.
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